AstraZeneca: supply contract with Samsung

(CercleFinance.com) - Samsung Biologics, the biopharmaceutical division of the South Korean tech giant Samsung, announced on Monday evening that it has signed a big supply contract with AstraZeneca.


The long-term agreement provides for the supply to the Anglo-Swedish laboratory of the main assets for the manufacture of its products, as well as the transfer of certain medicinal products.

The contract will mean a payment of around 330.8 million dollars, which could be increased to 545.6 million dollars if necessary, the Korean bioproduction services company said.


Copyright (c) 2020 CercleFinance.com. All rights reserved.